Home/Pipeline/Lebrikizumab

Lebrikizumab

Moderate-to-Severe Atopic Dermatitis

Regulatory ReviewFDA Review

Key Facts

Indication

Moderate-to-Severe Atopic Dermatitis

Phase

Regulatory Review

Status

FDA Review

Company

Eli Lilly

About Eli Lilly

Eli Lilly is a mission-driven pharmaceutical giant focused on discovering, developing, and commercializing medicines that address significant unmet medical needs in core therapeutic areas. The company has achieved monumental commercial success with recent blockbusters in diabetes (Mounjaro®/tirzepatide) and obesity (Zepbound®/tirzepatide), while also making historic strides in Alzheimer's disease with the approval of donanemab. Its strategy leverages deep scientific expertise across multiple modalities, a massive and diversified clinical pipeline, and a forward-looking commercial approach that integrates drug delivery with patient support services to secure long-term growth.

View full company profile

Therapeutic Areas

Diabetes Obesity Oncology Immunology Neuroscience Dermatology Autoimmune Sleep Disorders Migraine

Other Moderate-to-Severe Atopic Dermatitis Drugs

Drug	Company	Phase	Status
Amlitelimab	Sanofi	Phase 3	Active
Zumilokibart (APG777)	Apogee Therapeutics	Phase 2	Active - Part B enrollment completed
APG279 (Zumilokibart + APG990)	Apogee Therapeutics	Phase 1	Active - fully enrolled
Ebglyss/Lebrikizumab	Almirall	Marketed/Registration	Launched in EU; Under Review in US
IDgenix (AdvanceAD Tx)	Castle Biosciences	Commercial/Early Launch	Active
Rademikibart (CBP-201)	Connect Biopharma	Phase 3	Active